On September 24, Kirkland’s, Inc. (KIRK) announced that its Board of Directors authorized a new share repurchase program. The new program allows the company to repurchase up to $10 million worth of common shares. Kirkland’s still has $2.9 million available from its previous $10 million share repurchase program. Sonal alerted subscribers of the event […]
Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (IONS), announced positive topline clinical trial results on September 24. The Phase 2 clinical trial is studying the effect of AKCEA-APO(a)-LRx on patients with established cardiovascular disease and elevated levels of lipoprotein(a), known as Lp(a). The goal of the Phase 2 clinical study was to […]
On September 13, Progenics Pharmaceutical, Inc. (PGNX) reported Phase 3 clinical trial results from its study of 1404, the company’s prostate specific membrane antigen (PSMA). It is a targeted small molecule SPECT/CT imaging agent designed to visualize prostate cancer. The results met one of the co-primary endpoints of identifying patients without clinically significant prostate cancer. […]
On September 5, ProQR Therapeutics, N.V. (PRQR) announced positive results from its Phase 1/2 trial of QR-110 in patients with Leber’s congenital amaurosis 10 (LCA 10) due to a mutation in the CEP290 gene. LCA10 usually leads to childhood blindness and currently has no available treatment options. Patients in the trial had rapid and sustained […]
The August 2018 scorecard for the signals generated from Sonal can be downloaded here. For more information regarding how you can trade these signals, see the article The Three Moves for Event Based Trading Try Sonal 30 days for free and cancel anytime! Subscribe here and check out the Quickstart Guide
Let us send you a summary of the signals Sonal generates EVERY WEEK… and you can decide if you’re missing anything.